π§ TACSI Trial in NEJM (Sep 2025) challenges the status quo on dual antiplatelet therapy after CABG for ACS!
π¨ββοΈ 2201 patients across 5 Nordic countries
π Ticagrelor + Aspirin β better outcomes vs Aspirin alone
π No reduction in death, MI, stroke, or revascularization
π©Έ But bleeding (4.9% vs 2.0%) & dyspnea (18.2% vs 6.4%) increased
π Guidelines may need rethinking.
π Jeppsson A et al. N Engl J Med. 2025; DOI: 10.1056/NEJMoa2508026
#TACSI #Cardiology #CABG #DAPT #ACS #NEJM #PrecisionMedicine #RCT #BleedingRisk #ClinicalTrials